Ramón
García Sanz
Profesor Titular de Universidad
Jorge
Labrador
Publicaciones en las que colabora con Jorge Labrador (16)
2024
-
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
eClinicalMedicine, Vol. 71
-
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
Infection
-
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry
Hematological Oncology, Vol. 42, Núm. 1
2023
-
Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
International Journal of Infectious Diseases, Vol. 137, pp. 98-110
-
Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma
Cancers, Vol. 15, Núm. 5
2022
-
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Blood, Vol. 140, Núm. 26, pp. 2773-2787
-
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
Cancers, Vol. 14, Núm. 23
-
Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival
British Journal of Haematology, Vol. 198, Núm. 2, pp. 278-287
2020
-
Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited RUNX1 mutations without a pre-existing platelet disorder
Leukemia and Lymphoma
-
Reply to Brown et al: ‘Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis’
Leukemia and Lymphoma
2017
-
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
Leukemia, Vol. 31, Núm. 10, pp. 2094-2103
-
Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma
Haematologica, Vol. 102, Núm. 5, pp. 922-931
2015
-
A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma
Acta Oncologica, Vol. 54, Núm. 6, pp. 933-938
2014
-
ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma
Annals of hematology, Vol. 93, Núm. 10, pp. 1745-1753
2013
-
Kikuchi-Fujimoto disease: A case supporting a role for human herpesvirus 7 involvement in the pathogenesis
Rheumatology International, Vol. 33, Núm. 12, pp. 3065-3068
2012
-
The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: A rare disease with new clinical insights
European Journal of Haematology, Vol. 88, Núm. 5, pp. 450-454